The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

A new approach using lipid nanoparticles to deliver genetic material is showing promise in tackling two major challenges in ...

Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...

Researchers have built an AI-powered pathology tool designed to predict whether small cell lung cancer patients will respond ...

Screening individuals for lung cancer with low-dose CT on a nonrisk basis is associated with a marked reduction in lung cancer mortality and better overall survival, reveals Chinese data.

ORR 35.8% overall, 37.5% in second-/third-line, and 47.1% in light/nonsmokers, with median DOR not reached in key subsets. Exploratory efficacy suggested durable benefit in later lines, including ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

What Is Hernexeos, and Why Does It Matter? Hernexeos (zongertinib) is a prescription medicine known as a kinase inhibitor that is used for treating adults with advanced non-small-cell lung cancer ...

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E Advancements in profiling technologies have deepened our ...

Please provide your email address to receive an email when new articles are posted on . Patients with small cell lung cancer who had higher levels of detectable ctDNA mutations at diagnosis had worse ...

Immunotherapy targeting the programmed cell death (ligand)-1 (PD-[L]1) pathway has improved outcomes in patients with advanced/metastatic non-small cell lung cancer (NSCLC) without actionable genomic ...